C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter C—Drugs: GeneralPart 211—Current Good Manufacturing Practice for Finished PharmaceuticalsSubpart F—Production and Process Controls

21 C.F.R. § 211.100 (2026)

Written procedures; deviations

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 ACTIVE · 5 IN 5Y cited 1993–2026 10citing cases
At a glance

Courts have cited this section in 10 opinions since 1993, 5 of them in the last five years. The most litigated part is subsection (a) (1 case).

(a) There shall be written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess. Such procedures shall include all requirements in this subpart. These written procedures, including any changes, shall be drafted, reviewed, and approved by the appropriate organizational units and reviewed and approved by the quality control unit.

(b) Written production and process control procedures shall be followed in the execution of the various production and process control functions and shall be documented at the time of performance. Any deviation from the written procedures shall be recorded and justified.

The 10 cases that cite 21 C.F.R. § 211.100 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENCrocker v. Kv Pharm. Co., 782 F. Supp. 2d 760 (E.D. Mo. 2010).
cites § 211.100 2×cited by 12 cases
Where it cites § 211.100
“Failure to review and approve changes to written procedures by the quality control unit, as required by 21 C.F.R. § 211.100 (a); f. Failure to clean, maintain, and sanitize equipment and utensils at appropriate intervals to prevent contamination that would alter the safety,…”
Later courts cite it for
“had knowledge of or participated in underlying fiduciary breaches.” · 2 citing courts
2
REDPub. Pension Fund Grp. v. Kv Pharm. Co., 705 F. Supp. 2d 1088 (E.D. Mo. 2010).
cites § 211.100 2×cited by 4 cases
Reversed in part by Public Pension Fund Group v. KV PHARMACEUTICAL CO. (2012): the Court of Appeals for the Eighth Circuit's own opinion in this case ("Ill For the reasons stated, we affirm in part, reverse in part, and remand to…
Where it cites § 211.100
“Failure to review and approve changes to written procedures by the quality control unit, as required by 21 C.F.R. § 211.100 (a); F. Failure to clean, maintain, and sanitize equipment and utensils at appropriate intervals to prevent contamination that would alter the safety,…”
3
GREENUnited States v. Barr Labs., Inc., 812 F. Supp. 458 (D.N.J. 1993).
cites § 211.100 1×cited by 13 cases
Where it cites § 211.100
“” 21 C.F.R. § 211.100 . 74. These written procedures, in turn, must be verified.”
4
NO FLAGShareholder Rep. Servs., LLC v. Alexion Pharm., Inc., No. 2020-1069-MTZ (Del. Ch. May 27, 2026).
cites § 211.100 11×subsections: (a)cited by 0 cases
Where it cites § 211.100
“¶¶ 80–84 (describing Patheon’s manufacture process and concluding “Patheon failed to properly evaluate the differences between Suite #1 and Suite #2 and the impact the manufacturing differences may have had on product quality, in violation of cGMP requirements, per 21 CFR §§…”
5
NO FLAGKoshy v. Regeneron Pharm., Inc., No. 7:17-cv-07781 (S.D.N.Y. Dec. 18, 2019).
cites § 211.100 1×cited by 0 casesunknown
Where it cites § 211.100
“Plaintiff also appears to rely on 21 C.F.R. §§ 211.100 and 211.160. Those regulations mandate written change controls and contain general requirements for laboratory controls, respectively.”
6
NO FLAGSalzman v. ImmunityBio, Inc., 753 F. Supp. 3d 1050 (S.D. Cal. 2024).
cites § 211.100 1×cited by 0 casesunknown
Where it cites § 211.100
“(citing 21 C.F.R. § 211.100 ). 21 The FDA will not approve a biologic product if its production fails to comply with 22 the FDA’s minimum standards for drug manufacturing, otherwise known as current good 23 manufacturing practices (“cGMP”).”
7
NO FLAGPfizer Inc. v. State of Texas & Tarik Ahmed, No. 15-25-00021-CV (Tex. App.—15th Dist. Feb. 28, 2025).
cites § 211.100 1×cited by 0 cases
Where it cites § 211.100
“21 CFR § 211.100 . 16 21 CFR § 211.22 (a).”
8
NO FLAGPineda v. Lake Consum. Prods., Inc., No. 5:24-cv-01074 (E.D. Pa. Sept. 22, 2025).
cites § 211.100 1×cited by 0 casesunknown
Where it cites § 211.100
“¶ 24 (citing to 21 C.F.R. § 211.100 ), “laboratory controls” must include “establishment of scientifically sound and appropriate specifications.”
9
NO FLAGKouyate, No. 1:25-cv-01013 (W.D. Mich. Mar. 3, 2026).
cites § 211.100 1×cited by 0 casesunknown
Where it cites § 211.100
“Many of the cited cGMPs require manufacturers “to assure that the[ir] drug products have the identity, strength, quality, and purity they purport or are represented to possess,” 21 C.F.R. § 211.100 (a), or contain similar language.”
10
NO FLAGMylan Pharm., Inc. v. United Steel, 548 F. Supp. 2d 252 (N.D. W. Va. 2008).
cites § 211.100 1×cited by 0 cases
Where it cites § 211.100
“21 C.F.R. § 211.100 (b). Mylan contends that Jones violated this GMP by manipulating the test results and, thus, failing to keep accurate records.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199320092026

One bar per year. Tallest: 2 cases in 2010. 2026 is a partial year. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
E.D. Mo.2S.D. Cal.1Del. Ch.1W.D. Mich.1D.N.J.1S.D.N.Y.1E.D. Pa.1Tex. App.1

The 8 courts with the most citing cases, of 9 courts in all.

By subsection
(a)1 case
Shareholder Rep. Servs., LLC v. Alexion Pharm., Inc., No. 2020-1069-MTZ (Del. Ch. May 27, 2026).“¶¶ 80–84 (describing Patheon’s manufacture process and concluding “Patheon failed to properly evaluate the differences between Suite #1 and Suite #2 and the impact the manufacturing differences may have had on product quality, in violation of cGMP requirements, per 21 CFR §§…”
Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com